← FDA Drug Approvals (Drugs@FDA)

LUBIPROSTONE

ANDA · Abbreviated New Drug Application (Generic) · Sponsor: TEVA PHARMS USA INC · Approved 2022-01-18

Drug application

FDA Application #

ANDA209920

Application type

Abbreviated New Drug Application (Generic)

Brand name

LUBIPROSTONE

Generic name

LUBIPROSTONE

Active ingredients

LUBIPROSTONE

Dosage form

CAPSULE

Route

ORAL

Marketing status

Prescription

Sponsor

TEVA PHARMS USA INC

Manufacturer

Teva Pharmaceuticals, Inc.

First approval

2022-01-18

Source

Authoritative

Drugs@FDA application overview

Machine

JSON-LD · Markdown